| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 10.11 | 2.9% |
| Total Income | 10.11 | 2.9% |
| Expenditure | 13.27 | 0.6% |
| PBT | -2.82 | 15.3% |
| Net Profit | -3.01 | 13.3% |
| OPM | -31.22% | 4.59pp |
| NPM | -29.76% | 5.49pp |
| EPS | -0.07 | 12.5% |
Myomo Reports Q1 2026 Revenue of $10.1 Million, Up 3% Y-o-Y
08 May 2026 · 8 May, 1:51 am
Summary
Myomo, Inc. reported a 3% increase in revenue for the first quarter of 2026, reaching $10.1 million. The company saw a significant shift towards recurring patient revenue, which now represents 49% of total revenue. Gross margin improved by 100 basis points, leading to a 20% improvement in Adjusted EBITDA. Management expects sequential revenue growth in the second quarter, projecting revenue between $10.3 million and $10.8 million and reaffirmed full year revenue guidance of $43 million to $46 million.
Key Highlights
- 1
Myomo's first quarter revenue reached $10.1 million, reflecting a 3% increase compared to the first quarter of 2025.
- 2
Recurring patient sources accounted for 49% of the first quarter revenue, up from 25% in the prior year.
- 3
MyoPro orders received during the first quarter of 2026 increased by 12% year-over-year.
- 4
Gross margin expanded by 100 basis points year-over-year, contributing to a 20% improvement in Adjusted EBITDA.
- 5
The company's backlog as of March 31, 2026, was 226 patients, a 14% increase compared to December 31, 2025.
- 6
Operating loss for the first quarter of 2026 was $3.2 million, compared to $3.5 million for the first quarter of 2025.
- 7
The company expects second quarter 2026 revenue to be in the range of $10.3 million to $10.8 million.
Management Comments
Paul Gudonis
“Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient sources, increasing market access, demonstrating operating leverage and investing in innovation. With strong progress against each, first quarter revenue and operating results were above our targets. We are effectively shifting our business toward recurring patient sources, which represented 49% of revenue in the quarter, up from 25% a year ago. Our MyoConnect program is ramping up nicely and enhancing the clinical quality of prospective patients as well. This resulted in 11% of pipeline adds and 16% of orders generated by direct billing referrals in the quarter, with the added benefit of a sequential decline in cost per pipeline add. "With a strong backlog entering the second quarter, we expect to grow revenue sequentially with modestly higher operating expenses from increased advertising spend as changes made in our marketing program continue to gain traction,"
Informational and educational content only. Not investment advice.